Skip to content

Study · Case report or series · n = 1 · 2024

2 results

Delayed Type Hypersensitivity Reaction Induced By Liraglutide With Tolerance to Semaglutide.

Moreno-Borque R, Guhl-Millán G, Mera-Carreiro S, Pazos-Guerra M, Cortés-Toro JA, López-Bran E

JCEM case reports21 Jun 2024Cited by 4 (Europe PMC)

PMID38911363 (opens in a new tab)PMCIDPMC11191647 (opens in a new tab)DOI10.1210/jcemcr/luae105 (opens in a new tab)PepBankPUB-38911363
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the management of type 2 diabetes and obesity. It was the first GLP-1 receptor agonist to be approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of obesity. To date, numerous skin adverse reactions to liraglutide have been reported, but data regarding hypersensitivity reactions are scarce, raising concerns about its safety and clinical management. We present the case of a 56-year-old female patient with class 3 obesity who was started on subcutaneous liraglutide (Saxenda) by her endocrinologist. One month after starting the aforementioned treatment, the patient presented well-defined, round, erythematous pruriginous plaques surrounding the injection site, around 24 hours after the drug administration. A liraglutide-induced, delayed-type hypersensitivity reaction was suspected, which could be subsequently confirmed by allergy testing and histopathological study. This paper explores the clinical use of liraglutide, the occurrence of hypersensitivity reactions, diagnosis, management, and implications for future research. Understanding and managing liraglutide hypersensitivity is crucial to ensuring the safety and efficacy of this medication.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 56-year-old woman with class 3 obesity, subcutaneous liraglutide caused erythematous itchy plaques at the injection site, confirmed as delayed-type hypersensitivity by allergy testing and histopathology.

    In plain wordsIn one woman with obesity, liraglutide caused itchy red plaques at the injection site; tests confirmed a delayed allergic reaction.

    Peptide
    Liraglutide
    Outcome
    IncreaseDelayed-type hypersensitivity reaction at the injection site
    Study

    n = 1

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    One month after starting the aforementioned treatment, the patient presented well-defined, round, erythematous pruriginous plaques surrounding the injection site, around 24 hours after the drug administration.
    2 context sentences
    Summary · context
    A liraglutide-induced, delayed-type hypersensitivity reaction was suspected, which could be subsequently confirmed by allergy testing and histopathological study.
    Summary · context
    We present the case of a 56-year-old female patient with class 3 obesity who was started on subcutaneous liraglutide (Saxenda) by her endocrinologist.
  2. 02HumanCase report or seriesSafety outcome

    In a woman with delayed-type hypersensitivity to liraglutide, semaglutide was tolerated.

    In plain wordsIn one woman with a delayed allergic reaction to liraglutide, semaglutide was tolerated.

    Peptide
    Semaglutide
    Outcome
    No significant changeTolerance of semaglutide after liraglutide hypersensitivity
    Study

    n = 1

    Outcome group
    Adverse events · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Title
    Delayed Type Hypersensitivity Reaction Induced By Liraglutide With Tolerance to Semaglutide.
    1 context sentence
    Summary · context
    We present the case of a 56-year-old female patient with class 3 obesity who was started on subcutaneous liraglutide (Saxenda) by her endocrinologist.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.